HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

Pre-IPO B.J.ZH.F.Panther Medical Equipment - Insights on the Industry, the Business and the Concerns

China Healthcare Weekly (Oct.1) - A Landmark Document Released, Dental Implants, Core Data Security

Pre-IPO MicroPort CardioFlow - A Better Candidate of the TAVR Market in China?

Pre-IPO Shanghai Hanyu Medical Technology - Insights on the Industry and the Products

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Jenscare Scientific / Equity Capital Markets

<p>Cardiovascular medical device market has always been one of the largest segments in the global medical device industry. Among them, the interventional therapies of structural heart diseases, represented by transcatheter valvular therapeutics, are booming and have become a highlight in the field of cardiovascular diseases, bringing another revolution in interventional cardiology. On June 21, <a href="https://www.smartkarma.com/entities/jenscare-scientific-co-ltd" target="_blank" data-smartkarma-citation="entities:33525:1" rel="noopener">Jenscare Scientific (JCS HK)</a>, a globally influential medical device company dedicated to the development of innovative products for the treatment of structural heart diseases, submitted the prospectus to HKEX and officially started the IPO process. This insights mainly analyzed the industry characteristics, the business, the financial position and the related challenges.</p>

Cardiovascular medical device market has always been one of the largest segments in the global medical device industry. Among them, the interventional therapies of structural heart diseases, represented by transcatheter valvular therapeutics, are booming and have become a highlight in the field of cardiovascular diseases, bringing another revolution in interventional cardiology. On June 21, Jenscare Scientific (JCS HK), a globally influential medical device company dedicated to the development of innovative products for the treatment of structural heart diseases, submitted the prospectus to HKEX and officially started the IPO process. This insights mainly analyzed the industry characteristics, the business, the financial position and the related challenges.

Shanghai Hanyu Medical Technology (SHM HK)

Pre-IPO Jenscare Scientific - The Industry Characteristics, the Business and the Challenges